Martin Babler
Equibles does not estimate personal net worth.
About Martin Babler
Neurogene Inc. reported in an 8-K filed December 19, 2023 that Martin Babler resigned as director, effective December 18, 2023. Neurogene Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neurogene Inc. includes David J. Main (CEO), Donna M. Cochener (CEO), Rachel McMinn (CEO, Chairman and Board Member) and 7 others.
“On the Separation Date, Martin Babler, M. Cantey Boyd, Erin Lavelle and Todd Simpson resigned from Neoleukin's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.”
Affiliation history
-
Neurogene Inc. (NGNE)
SEC 8-K
Current2022-03-02–present
-
2020-01-01–2023-12-18
Company network
Leadership on record at Neurogene Inc.
- David J. Main CEO
- Donna M. Cochener CEO
- Rachel McMinn CEO, Chairman, Board Member
- Christine Mikail CFO, Board Member
- Christine Mikail Cvijic CFO
- Jonathan Drachman CFO
- Robert Ho CFO
- Sean Smith CFO, Chief Accounting Officer
- Donna Cochener General Counsel
- Cory Freedland Board Member